Fibrimage

Drug Profile

Fibrimage

Alternative Names: Fibrimage; Imagex™

Latest Information Update: 29 Mar 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Savient Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 27 Mar 2006 Discontinued - Phase-III for Diagnostic imaging in Canada (IV-injection)
  • 10 May 2005 Data from a media release have been added to the adverse events and Diagnostic Disorders therapeutic trials sections
  • 10 May 2005 Draxis has completed a phase III trial in Diagnostic Disorders in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top